Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its technology platforms include AB569, MetaBlok, Arch Inflammation, Borg and MetaMx. AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. MetaBlok is a drug candidate targeting sepsis, cancer metastasis and inflammation based diseases. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Inflammation is focused on developing anti-inflammatory small molecules that target proteins in the innate immune system. Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation. MetaMx are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The Company has not generated any revenues.